MRSA Screening & Bloodstream Infections

MRSA Colonization
MRSA costs U.S. hospitals $3.2 - $4.2 billion annually, and patients with MRSA spend up to 10 days longer in the hospital than those with methicillin-sensitive Staphylococcus aureus (MSSA) infections.2 Once colonized with MRSA, 30-50% of patients become infected.3, 4 That’s why active MRSA screening programs are so important for the control and prevention of MRSA. Because when MRSA is everywhere, you need a test for everyone.


MRSA Bloodstream Infections
Bloodstream infections with MRSA can cause significant morbidity and mortality and can have considerable impact on healthcare-related costs. The impact on patient outcome is tremendous.

  • MRSA bacteremia results in $71,715 in additional total hospital costs, and length of stay is 10 days longer compared to MSSA bacteremia.5

spectra

*Patent pending

Spectra™ MRSA
To aggressively address the rising MRSA epidemic you need a reliable partner that can help you respond efficiently and economically to the challenge. That’s why we are proud to offer Spectra™ MRSA for effective MRSA screening. This selective chromogenic medium is intended for use in the detection of nasal colonization of MRSA and MRSA from positive blood cultures demonstrating Gram-positive cocci on Gram stain. See Instructions for Use for detailed procedure.

  • Rapidly and economically detects nasal colonization of MRSA and MRSA from positive blood cultures
  • Aids in the prevention of MRSA infections
  • Delivers high Positive Predictive Value (PPV) to reduce unnecessary costs
  • Enables quick, efficient screening of patients
  • Produces easy-to-read, denim blue colonies on an opaque background
  • Requires no special handling for optimal workflow 24/7
Product InformationPackagingREF
Spectra™ MRSA10 Plates/PkR01821
100 Plates/PkR01822

References

  1. Jarvis, W.R., et. al. American Journal of Infection Control; 2007; 35(10):631-37.
  2. U.S. Outcomes Research Group of Pfizer Inc. Presented at the International Society for Pharmacoeconomics Outcome Research Meeting; 2005.
  3. Hall, G., and D. Flayhart. Infection Control Today; February 2006.
  4. Klevens, R.M., et. al. Clinical Infectious Disease; 2006; 42:389-91.
  5. Ben-David D., et. al. Infection Control Hospital Epidemiology; 2009; 30:453-460.

Make Your Move Before
Healthcare-Associated Infections Do.

Prevention starts with preparation. That's why we developed a total solution for MRSA screening,
C. dIff testing, and VRE screening. To help control the spread, these Healthcare-Associated Infection control products are designed to deliver rapid, reliable results. For your hospital, that means better patient management. For your patients, it means everything.

REQUEST INFORMATION

Cost Analzyer